Impact of the Cancer and Aging Research Group (CARG) chemotherapy toxicity (tox) risk score on the benefit of a geriatric assessment–driven intervention (GAIN) among older adults with cancer.
Christiana Crook(City of Hope), Daneng Li(City Of Hope National Medical Center), Marianna Koczywas(City Of Hope National Medical Center), William Dale(City of Hope), Vincent Chung(City of Hope), Enrique Soto‐Pérez‐de‐Celis(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Reena Jayani(Vanderbilt University Medical Center), Mina S. Sedrak(University of California, Los Angeles), Can‐Lan Sun(University of Minnesota), Marwan Fakih(City of Hope), Kemeberly Charles(City of Hope), Monica Trent(University of California, Irvine Medical Center), Vani Katheria(City of Hope), Heeyoung Kim(City of Hope), Elsa Roberts(City of Hope), Leana Cabrera Chien(City of Hope), Jeanine Moreno(City of Hope), Joseph Chao(Amgen (United States))
Cited by 1
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564